M&A / Deals Lilly boosts ADC portfolio with CrossBridge Bio deal BioPharma DiveWorth up to $300 million, the buyout is Lilly s latest of an ADC maker and adds technology for making dual-payload therapies.M&A / DealsOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) BioPharma Dive Worth up to $300 million, the buyout is Lilly s latest of an ADC maker and adds technology for making dual-payload therapies. M&A / DealsOncologyRead full story Post navigation Previous: Lilly investing billions to prepare for overseas oral GLP-1 launchesNext: With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026 Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
